Cipla Remains Upbeat On Abraxane As US Generic Competition Looms

Indian Firm Continuing Talks With FDA For Complex ANDA Product

 
• By Dean Rudge
  
Sales growth concept
GxAbraxane is one of several assets set to boost Cipla's top line • Source: Alamy
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Business

More from Generics Bulletin